Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

PURPOSE: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189949/
https://www.ncbi.nlm.nih.gov/pubmed/33748921
http://dx.doi.org/10.1007/s10549-021-06145-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189949/
https://www.ncbi.nlm.nih.gov/pubmed/33748921
http://dx.doi.org/10.1007/s10549-021-06145-3

Ejemplares similares